Ethics & Informed Consent: Randomised Controlled Trial (RCT) (South Korea)
A detailed academic review of the ethical submission protocol, informed consent prerequisites, and reporting standards for conducting a Randomised Controlled Trial (RCT) within the regulatory framework of South Korea.
1. Ethical Principles & Legislative Framework
In research involving human participants, securing ethical clearance is a critical first step. For a Randomised Controlled Trial (RCT) being conducted in South Korea, study designs must align with the primary regulatory legislation: Bioethics and Safety Act. This statutory framework ensures participant welfare, confidentiality, and voluntary involvement are protected.
National Ethics Board Clearance Pathway
In South Korea, human research is monitored under the Bioethics and Safety Act. IRB reviews check that de-identification matches PIPA guidelines and that consent is documented.
Administrative review and formal approval are managed by a local or regional Institutional Review Board (IRB). Researchers must secure full approval or a formal exemption certificate from this board before recruiting any participants or commencing data collection.
2. Study Design Elements & Reporting Integrity
For a Randomised Controlled Trial (RCT), the review board places significant focus on methodological transparency. The application must outline the research rationale, recruitment protocols, inclusion and exclusion criteria, and data protection measures.
Study Classification: High Risk (Interventional)
As an interventional design, RCTs require rigorous safety oversight, clear allocation concealment, and predefined emergency unblinding pathways.
To guarantee academic integrity and reproducibility, the study report and subsequent publications should follow the internationally recognised reporting standard: CONSORT statement.
Special Directive: Interventional Study Protocols
Because this study design is classified as interventional, the Institutional Review Board (IRB) requires pre-registration of the trial on a public clinical registry (e.g. ClinicalTrials.gov or a regional WHO-compliant database) before patient enrolment begins. A detailed adverse event reporting protocol must also be submitted.
3. Informed Consent & Information Sheet Guidelines
A robust participant information sheet and informed consent form are critical parts of the ethical application. Ensure your documentation incorporates the following components:
Design-Specific Consent Focus Areas
Explicit random assignment details, placebo justification guidelines, active side effect monitoring, and safety thresholds.
- Plain Language Explanations: Avoid complex medical or technical terminology. Ensure readability matches the general population.
- Voluntary Participation: Explicitly state that participation is entirely voluntary and that individuals can withdraw at any time without negative consequences.
- Confidentiality & Data Controls: Explain how participant data will be anonymised or pseudonymised, who will have access to it, and how long it will be securely retained under Personal Information Protection Act (PIPA).
- Risk/Benefit Disclosure: Clearly list any potential risks, discomforts, or direct benefits associated with participation in the study.
- Ethics Board Contact Information: Provide the contact details of the reviewing Institutional Review Board (IRB) so participants can reach out if they have questions or concerns.
Research Ethics, Clinical Trials & Institutional Governance
To run a high-quality Randomised Controlled Trial (RCT) in South Korea, the protocol must strictly observe the Declaration of Helsinki ethical principles for clinical trials. Under active regulations, investigators must explicitly justify if any temporary deception in psychological research is planned for patients. The communication process must uphold the core ethical principles of informed consent, detailing voluntary withdrawal rights. Pre-requisites for starting the trial include a formal clinical trial registration and a signed clinical trial agreement contract. The research team must document all safety parameters to obtain complete research ethics approval from the Institutional Review Board (IRB). In accordance with South Korea participant safety rules, investigators must complete certified human protection modules before recruitment begins.
4. Regulatory Checklist Table
To streamline your ethical review submission, use the structured alignment checklist below:
| Requirement | Institutional Review Board (IRB) Standard | CONSORT statement Standard |
|---|---|---|
| Consent Form | Signed and dated prior to study activity. Focus: Explicit random assignment details. | Fully documented recruitment and consent paths. |
| Risk Management | Comprehensive risk mitigation plan. Mandates establishing an independent Data Safety Monitoring Board (DSMB) and registering the trial on a public registry (e.g., ClinicalTrials.gov). | Adverse events reporting strategy. |
| Data Retention | Compliance with local data protection rules (Personal Information Protection Act (PIPA)). | Provision of open-data options where possible. |
5. Academic & Research Infrastructure Matrix (South Korea)
The following authenticated registry lists top scientific organizations, clinical laboratories, and research hospitals in South Korea mapped via the Research Organization Registry (ROR) standards-compliance framework.
| Organization Name | Sector Type | Registry Identification |
|---|---|---|
| Korea Kacoh (South Korea) | company | ROR ID |
| Korea Innotech (South Korea) | company | ROR ID |
| Pharmbio Korea (South Korea) | company | ROR ID |
| Kolmar Korea (South Korea) | company | ROR ID |
| Korea Pharma (South Korea) | company | ROR ID |
| TEI Korea (South Korea) | company | ROR ID |
| Korea Yakult (South Korea) | company | ROR IDWikidata/Wiki |
| VSL Korea (South Korea) | company | ROR ID |
| Korea Telecom (South Korea) | company | ROR IDWikidata/Wiki |
| Bioland (South Korea) | company | ROR ID |
| Seeders (South Korea) | company | ROR ID |
| AnyGen (South Korea) | company | ROR ID |
| (주)인실리코젠 | company | ROR ID |
| Qurient (South Korea) | company | ROR ID |
| Adipogen (South Korea) | company | ROR ID |
6. Frequently Asked Questions
How long does the review process normally take?
Review timelines depend on the volume of applications and whether your proposal qualifies for expedited review. On average, a standard review by an ethics board in South Korea takes between 4 to 8 weeks.
Can we use digital signatures for informed consent?
Yes, digital consent forms are increasingly accepted, provided the platform used is secure, authenticates the identity of the signer, and complies with local regulations such as the eIDAS or ESIGN Act, depending on country-specific rules.
Regulatory Context
Verified Funding Bodies
Funder registries and DOI configurations verified for compliance in South Korea via Crossref.
- Korea Christian UniversityID: 501100002513 | Location: South Korea
- Sogang UniversityID: 501100002646 | Location: South Korea
- Yonsei UniversityID: 501100002573 | Location: South Korea
- National Research Foundation of KoreaID: 501100003725 | Location: South Korea
- Ministry of Science and ICT, South KoreaID: 501100014188 | Location: South Korea
- National NanoFab CenterID: 501100019956 | Location: South Korea
- Ministry of the Interior and SafetyID: 501100012261 | Location: South Korea
- Agency for Defense DevelopmentID: 501100005073 | Location: South Korea
- Konkuk University Medical CenterID: 100019704 | Location: South Korea
Pre-Submission Warning
Do not recruit participants or initiate study procedures before receiving official written approval from your reviewing board. Ethical approvals cannot be granted retrospectively under Bioethics and Safety Act.
